The antithrombotic efficacy of low-dose aspirin is well established. Its primary clinical effect
is mediated by inhibition of platelet cyclooxygenase-1, which reduces thromboxane A2 …

is a cause for concern. Once again, information relating to a major policy area is
communicated to the public ahead of any preparation or prepared response from the …

BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people
who already have occlusive vascular disease. We have assessed the benefits and risks in …

5 Meade TW. Determination of who may derive most benefit from aspirin in primary
prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–17. 6 …

Aspirin remains one of the most extensively studied cardiovascular medications in the
history of medicine. However, despite multiple, well-designed, large randomized controlled …

In The Lancet today, the Antithrombotic Trialists'(ATT) Collaboration reports on an individual
participant data meta-analysis of primary prevention with aspirin. 1 The ATT investigators …

Abstract We updated the 2002 Antiplatelet Trialists' Collaboration meta‐analysis of
antiplatelet therapy to assess the effects of aspirin alone in the secondary prevention of …

Background The use of aspirin in the primary prevention of cardiovascular events remains
controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in …

Aims The role of aspirin in the primary prevention setting is continuously evolving. Recent
randomized trials have challenged the role of aspirin in the primary prevention setting …

Cardiovascular disease causes one of every three deaths in the United States and costs this
country about $450 billion annu ally. 1 Each year, despite recent improvements in …